The Ministry of Industry and Information Technology responded to individual medicines shortage: 18 provinces have incorporated shortage drugs into the reserve directory

Cover news reporter Teng Yan

On September 14, Zhou Jian, deputy director of the Consumer Products Industry Department of the Ministry of Industry and Information Technology, disclosed when talking about individual drug shortages that 18 provinces have incorporated shortage drugs into the reserve directory.

On the same day, the Ministry of Industry and Information Technology held the seventh press conference of the "New Era Industrial and Information Development" series of press conferences, and its theme was "Promote the Consumer Product Industry Added Variety Make Quality Creation Brands".

Zhou Jian said that since the 18th National Congress of the Communist Party of China, the Ministry of Industry and Information Technology has adopted a variety of measures to solve the problem of drug shortage and achieved positive results.

▲ Zhou Jian, deputy director of the Consumer Products Department of the Ministry of Industry and Information Technology (Picture Source: Ministry of Industry and Information Technology)

The first is to establish a "shortage drug production supply monitoring and early warning platform". Conjugated with the Health and Health Commission, the Medical Insurance Bureau, and the Drug Administration issued the "Notice on Strengthening the Monitoring of Drug Production Reserve in centralized procurement in centralized procurement of national organizations", dynamically grasped clinical must be prone to shortage drugs, national central procurement selected drug production, supply and inventory The situation, strengthen early warning analysis, and ensure the stable supply of drugs. As of now, monitoring has covered 577 companies with 577 types of prone to shortage, and the national centralized procurement of the top six batch of 338 Chinese selected companies 250 varieties, monitoring the shortage of drugs or potential shortage of drugs from the production side.

The second is to organize the construction of small varieties (shortage medicines) to centralize production bases. Organize upstream and downstream enterprises to establish a drug supply guarantee consortium, and conjugate with relevant departments to identify 6 consortia to centralized production base construction units for small varieties (shortage drugs), which guarantees the stable production and supply of 100 small varieties. Support leading enterprise joint scientific research units, raw and drug production enterprises to establish a rare public service platform and rare disease medicine "industry -university -research" cooperation platform, incorporate rare diseases into small variety drugs and shortage drug supply guarantee, and promote rare disease medicines Continuously stable production.

The third is to establish a central and local two -level normal shortage of drug reserves. In 2021, the Ministry of Industry and Information Technology will revise the management measures of the national pharmaceutical reserve with relevant departments, further improve the national pharmaceutical reserve system that is responsible for, complementary and efficient in the central and local grades, and improves the reserve system, including clinical necessary shortage drugs. On the basis of emergency protection, the establishment of the central and local two -level normal shortage of drug reserves. At present, 18 provinces have included shortage drugs into the reserve directory, giving full play to the national pharmaceutical reserve function, and improving drug supply guarantee capabilities.

Zhou Jian said that in the next step, it will continue to strengthen the monitoring and early warning and production and supply guarantee of susceptible shortages, expand the channels for drug information monitoring, and promote the realization of the drug production side with the use of information sharing and accurate docking. Mobilize the production enthusiasm of enterprises, support the development of drug supply guarantee, deepen supply chain collaboration, and promote the integrated development of key varieties and drugs and preparations.

- END -